Partner Content Partner Content Spotlight on Key Sessions You Cannot Miss at Ophthalmic Drug... Are you aware the ophthalmic market is expected to reach $21 billion by the year 2022?
News RevMed hails first-line data with pancreatic cancer drug Revolution Medicine's fast-growing pan-RAS inhibitor Rasonque has generated exciting results as a first-line treatment for pancreatic cancer.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.